Cargando…

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury

BACKGROUND: The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidney disease. However, its effects on vascular function remain elusive. PURPOSE: The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dutzmann, Jochen, Musmann, Robert-Jonathan, Haertlé, Marco, Daniel, Jan-Marcus, Sonnenschein, Kristina, Schäfer, Andreas, Kolkhof, Peter, Bauersachs, Johann, Sedding, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605005/ https://www.ncbi.nlm.nih.gov/pubmed/28926607 http://dx.doi.org/10.1371/journal.pone.0184888

Ejemplares similares

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury
por: Daniel, Jan-Marcus, et al.
Publicado: (2014)

Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation
por: Daniel, Jan-Marcus, et al.
Publicado: (2012)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
por: Jerome, Jack R., et al.
Publicado: (2023)

Emerging translational approaches to target STAT3 signalling and its impact on vascular disease
por: Dutzmann, Jochen, et al.
Publicado: (2015)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration
por: Dutzmann, Jochen, et al.
Publicado: (2022)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
por: Di Lullo, Luca, et al.
Publicado: (2023)

Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone
por: Pollard, Celina M, et al.
Publicado: (2022)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis
por: Pei, Hui, et al.
Publicado: (2018)

Abstract 1: Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis
por: Dutta, Deep, et al.
Publicado: (2022)

Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease
por: Sedding, Daniel G., et al.
Publicado: (2018)

Suppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628
por: Ma, Frank Y., et al.
Publicado: (2015)

Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy
por: Yao, Lan, et al.
Publicado: (2023)

Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice
por: Napp, L. Christian, et al.
Publicado: (2016)

Erratum to: ‘Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice’
por: Napp, L. Christian, et al.
Publicado: (2016)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

Deficiency of neuropeptide Y attenuates neointima formation after vascular injury in mice
por: Peng, Song, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Gastrodin inhibits cell proliferation in vascular smooth muscle cells and attenuates neointima formation in vivo
por: ZHU, LIHUA, et al.
Publicado: (2012)

MMP-9 Deletion Attenuates Arteriovenous Fistula Neointima through Reduced Perioperative Vascular Inflammation
por: Shih, Yu-Chung, et al.
Publicado: (2021)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4ggb864stbuecmnfbnvh433dfh